Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease.
Rammo R, Rock A, Transou A, Raghunathan A, and Rock J. Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease. J Neurosurg 2016; 124(2):496-500.
Journal of neurosurgery
Meningiomas are common intracranial tumors categorized as Grades I-III per the current WHO guidelines. A small percentage of meningiomas are Grades II and III, which are likely to recur after initial treatment. Grade III meningiomas are considered to be malignant and warrant aggressive management. If surgery and radiation fail to produce lasting remission, effective treatment options for patients with progressive anaplastic meningiomas are elusive. The authors present the case of a patient with a meningioma that gradually progressed from Grade I to Grade III over 12 years despite repeated surgery and radiation therapy. The patient has been in remission for over 3 years following octreotide therapy.
Medical Subject Headings
Adult; Antineoplastic Agents, Hormonal; Brain Neoplasms; Combined Modality Therapy; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Meningioma; Neoplasm Recurrence, Local; Octreotide; Treatment Outcome